Vanguard Personalized Indexing Management’s Arcus Biosciences RCUS Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$233K	Buy	+10,773	New	+$233K	﹤0.01%	1742

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Personalized Indexing Management's RCUS Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Arcus Biosciences (RCUS) in Q1 2026: 10,773 shares worth $233K. The stake represents ﹤0.01% of the portfolio and ranks #1742 among its holdings.

210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

Vanguard Personalized Indexing Management held 10,773 shares of Arcus Biosciences worth $233K as of Q1 2026.
Arcus Biosciences was a new Vanguard Personalized Indexing Management position in Q1 2026.
Arcus Biosciences made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #1742 holding.
210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.